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NEWS

The End of the AZT Patent: A New
Beginning or Too Little Too Late?
By Lindsay Frank
AIDS patients may soon find it more
affordable to gain access to a drug known to extend
the quality and longevity of their lives. After over
seventeen years, GlaxoSmithKline's ("GSK") patent
on AZT, an anti-retroviral drug used to stop the
reproduction of the AIDS virus in the body and a staple
in the drug regimen for those living with HIV and AIDS,
has finally come to an end.'
Critics of the patent believe that the
pharmaceutical giant made their drugs so unaffordable

with HIV and AIDS.' Their lawsuit against the
pharmaceutical giant alleges that GSK illegally excluded
competition for anti-viral drugs, such as AZT, Ziagen
and 3TC, and priced their drugs so high above
competitive market rates that they became out of reach
for many patients.9 As a provider of treatment for the
uninsured and patients who otherwise would not be
able to afford to pay for their medication, the AIDS
Healthcare Foundation also seeks damages for paying
what they consider to be grossly inflated prices for
AZT and other derivative AIDS drugs.Io
Initially developed by the National Institute of
Health in 1964 as a possible cancer drug, AZT became
known worldwide as the first life-saving and lifeenhancing drug for AIDS patients otherwise faced with

"We are hopeful the the end of GSK's patent on AZT means generic versions of
the drug will now be more readily available, but this does not change the fact
that there was an illegitimate patent in the first place." -- Tom Meyers
that some people suffering from HIV and AIDS have
died prematurely due to their inability to pay for the
requisite medications. 2 While AIDS activists across
the country are thrilled to see the end of GSK's patent,
they are not convinced that it will make drugs used to
fight the virus more accessible and affordable for all
patients.3
GlaxoSmithKline also has a patent on
Combivir and Trizivir, which combines AZT and two
or three other medications in one pill.4 Commonly
known as "drug cocktails," these antiretroviral
combination therapies ("ARVs") make it more
convenient for patients to adhere to a regular treatment
plan and have become the most widely used
medications among HIV/AIDS patients in the world.'
However, due to the rising popularity ofARVs, individual
sales of AZT have declined significantly, thereby
downplaying the effect of the patent's expiration.6
AIDS activists have been frustrated with
GSK's control over the HIV/AIDS drug market for
years. In fact, in April 2003, the AIDS Healthcare
Foundation filed an amended patent piracy lawsuit
against GSK in federal district court.7
The AIDS Healthcare Foundation, a non-profit
organization, is the United States' largest provider of
healthcare services and treatment for individuals living
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almost certain death. " GSK obtained the patent for
AZT in the 1980s and began pricing it well above
competitive rates.12
Representatives from the AIDS Healthcare
Foundation further claim that GSK lied to the patent
office about discovering the drug. 3 A patent on AIDS
therapy drugs prohibits other companies from
marketing more affordable but equally effective generic
versions. This is especially detrimental to poorer
countries that are forced to import their drugs from
the West and pay the exceedingly high prices set by
Western manufacturers.14
While optimistic about the future, Tom Myers,
general counsel for the AIDS Healthcare Foundation,
refused to undermine the detrimental consequences
he believes GSK's patent caused in the first place. 5
"We are hopeful that the end of GSK's patent on AZT
means generic versions of the drug will now be more
readily available, but this does not change the fact that
there was an illegitimate patent in the first place,"
Meyers said.16 "Our lawsuit focuses on the
[irreversible] harm that has occurred over the past
seventeen years."l 7
On the other hand, some activist groups
believe that the AIDS Healthcare Foundation's
(AZT Patent, continuedon page 5)
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$6.7 Million Settlement in Special
Education Case

(AZT Patent, continuedfrom page 4)

claims are misplaced. These groups believe that the
pressure to get AZT out on the market as well as the
research and development costs that went into the
An autistic child and his parents agreed to production of AZT may justify its high price. "AZT
a settlement amount of $6.7 million in their six- was rushed through FDA approval in record setting
year long administrative and legal battle with the time, at a pace that has yet to be equaled," said
Manhattan Beach Unified School District ("School Martin Delaney, founding director of Project InDistrict") and the California Department of form." "The production methods for making AZT at
Education ("CDE")i
that time were relatively primitive and required some
District Court Judge Gary Allen Feess bizarre and expensive raw materials." 19 Delaney
approved the record settlement amount, which also went on to say, "AZT is by no means a drug
represents payment to the child and his parents for that stands out from the pack because of pricing."2 0
the School District and CDE's failure to
Many generic versions of common AIDS
appropriately educate the child for more than five drugs may cost between 200 and 300 percent less
years.
than their American-made brand name counterparts.
"This lawsuit could have been avoided and For instance, the cost of treating an AIDS patient with
millions of dollars could have been saved had the patented drugs can cost between $10,000 and $15,000
Manhattan Beach USD and the CDE simply per year, but a similar generic brand regime can cost
complied with clearly established statutes and $1 per day.2 2 Despite the fact that drug companies
regulations," said Steven Wyner, attorney for the such as GSK have cut the prices of AIDS drugs sold
family.
to African nations, critics argue that the drugs are still
Under the Individuals with Disabilities not being sold as cheaply as genenc versions produced
Education Act ("IDEA"), the School District is required in countries such as India, Thailand and Brazil. 23
to provide students with disabilities a "free appropriate
The average cost of a drug combination
4
the
government
funds
education."
The
federal
public
therapy taken by AIDS patients in the United States is
IDEA in an effort to support the education of disabled $14,000 per year.2 4 GSK currently controls 40% of
children.' In order to receive the federal funding, states the AIDS drug market in the United States and profits
and local educational agencies must have in place statutory from the sale of the company's worldwide sale of AIDS
polices and procedures that ensure identification and drugs are estimated to run in excess of $2 billion each
year.25
By Katie D. Fletcher

(Special Education, continued on page 6)
'Glaxos Patent Protectionof FirstAIDS Drug, AZT ends;
AHF Blasts Glaxo's & Drug Industry's Greed, PR
Newswire, Sept. 17, 2205, http://www.prnewswire.co.uk/
cgi/news/release?id=153887.
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The Manhattan Beach Unified School District failed to
provide adequate education for one of its disabled students.

Loses Another Key Round in AIDS Healthcare
Foundation'sAZT PatentPiracy Case, PR Newswire (May
3,2004), http://www.prnewswire.co.uk/cgi/news/
release?id= 122068.
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